Imiquimod: Effects on Skin Lesions

Imiquimod (brand names Aldara, Zyclara and generics) is an immunomodulator that stimulates the local immune response through activation of Toll-like receptor 7 (TLR7) and to a lesser extent TLR8. Unlike classic antiseptics or antifungal agents, imiquimod works indirectly: it activates the body's own defense against skin lesions, from genital warts to actinic keratosis to superficial basal cell carcinoma. This mediation via the immune system explains the characteristic appearance of therapy with marked inflammatory skin reaction at the application site.

Imiquimod has been approved in the USA since 1998 and in Europe since 2002. In Germany, the substance is available as a 5 percent cream and as a 3.75 percent cream. Application should be in the hands of experienced general practitioners or dermatologists, as the indications, treatment regimen, and expected local reactions must be carefully discussed. Those using imiquimod for the first time are often surprised by the strength of the skin reaction, which is however a desired sign of immunological activity.

Mechanism of Action

Imiquimod binds to Toll-like receptor 7 on dendritic cells, macrophages, and certain other immune cells. Activation of TLR7 leads to the release of pro-inflammatory cytokines such as interferon alpha, tumor necrosis factor alpha, interleukin 12, and a cascade of downstream mediators. This activates cytotoxic T cells, natural killer cells, and antigen-presenting cells, which strengthens local immune defense against virally and tumorally altered cells.

In genital warts (condylomata acuminata), this activation leads to elimination of HPV-infected keratinocytes. In actinic keratosis, preneoplastic cells are recognized and destroyed. In superficial basal cell carcinoma, cytotoxic effects target tumor cells, which in carefully selected patients can lead to lasting remission. The effect builds up over several weeks and depends on individual immune competence.

Topically, imiquimod is absorbed to only a minimal extent (less than one percent of the applied dose), systemic effects are rare and usually mild (flu-like symptoms). The effect occurs mainly locally at the treated area, with controlled inflammatory reaction being part of the therapeutic concept.

Indications

• Genital warts (condylomata acuminata) in the external genital and perianal area in adults aged 18 and over
• Actinic keratosis on the face and scalp in non-immunosuppressed adults
• Superficial basal cell carcinoma when surgery is not possible or is to be avoided, especially on cosmetically sensitive areas
• Off-label use in lentigo maligna, Bowen's disease, molluscum contagiosum, verrucae vulgares in specialized cases

Imiquimod is not first choice for deep or nodular basal cell carcinomas, where surgery is standard. Application is not approved for intraurethral, intravaginal, intraanal, or cervical genital warts. Also wait until after treatment of acute skin infection or open wounds before therapy begins.

Dosage and Application

Genital warts: Apply imiquimod 5 percent thinly, three times per week in the evening, allow to work for 6 to 10 hours, then wash off with water and mild soap. Duration of therapy until healing, maximum 16 weeks.

Actinic keratosis 5 percent: Once daily in the evening, three times per week for four weeks, followed by four weeks of rest. Second cycle if needed.

Actinic keratosis 3.75 percent: Once daily in the evening for two treatment cycles of two weeks each, with two weeks of rest between cycles.

Superficial basal cell carcinoma: Once daily in the evening, five times per week for six weeks, followed by observation and reevaluation.

Application technique: Wash hands first, apply cream thinly and only to affected areas, then wash hands again. Do not apply to healthy skin, eyes, lips, or mucous membranes.

Sun protection: During therapy and for several weeks afterwards, avoid intense UV exposure, use sun protection factor 50 or higher, as the skin is more sensitive.

Therapy breaks: In case of very pronounced skin reaction, take individual breaks, a short interruption usually does not harm effectiveness.

Side Effects

Very common: Skin redness, burning, pain, itching, formation of crusts or scales, erosions, swelling at the application site. These local reactions are an expected sign of therapy.

Common: Headaches, fatigue, muscle or joint pain, mild flu-like symptoms.

Occasional to rare: Ulcerative skin changes, hyperpigmentation or hypopigmentation, local bacterial secondary infections, allergic skin reactions, temporary lymph node swelling.

Systemic: Very rarely fever, chills, generalized skin reactions, temporary elevation of liver values, worsening of psoriatic skin changes, triggering of autoimmune phenomena such as vitiligo.

Pregnancy and breastfeeding: Data limited, use only after individual consultation.

Drug Interactions

• Topical glucocorticoids: inhibit the immunological reaction, thereby reducing the effectiveness of imiquimod. Ideally avoid during therapy.
• Other local acne therapeutics or retinoids: increased skin irritation, concurrent use only under dermatological supervision.
• Systemic immunosuppression (glucocorticoids, calcineurin inhibitors, biologics): reduced effectiveness of imiquimod, individual indication.
• Live vaccines: no direct contraindication, but with active imiquimod therapy and pronounced immunological reaction, individual decision.
• Other acne therapies such as adapalene: combination for acne therapy not with imiquimod (different indication).

Special Precautions

Pregnancy: Data limited. Use during pregnancy is not recommended unless there is a clear indication and after individual consultation. Breastfeeding: Avoid application in the breast area and in the immediate vicinity of the nipple, otherwise the substance is acceptable in many cases due to low absorption, always after consultation with pediatrics and gynecology.

Children: Aldara approved for genital warts from age 18 onwards. Off-label use in molluscum contagiosum may be considered individually, but should be in dermatological hands.

Immunosuppressed patients: Reduced effectiveness, often stronger local reactions. Indication should be restrictive and individual.

Skin conditions: Exercise caution in psoriasis, as imiquimod can trigger flare-ups. With active skin infection, treat the infection first, then imiquimod.

Before starting therapy: Consultation about skin reaction, treatment plan, behavior with strong irritation and therapy breaks, sun protection, follow-up examination after completion of therapy.

Sexual partners: In genital warts, sexual partners should be examined by a doctor, as HPV is often present bilaterally. Avoid sexual intercourse during application, as cream can reduce the effectiveness of condoms and diaphragms.

Lifestyle: In actinic keratosis, the underlying UV damage to the skin is part of therapy success. Consistent sun protection and regular skin cancer screening are essential.

You might also be interested in

• Adapalene, topical retinoid for acne
• Isotretinoin, systemic retinoid for severe acne
• Fluorouracil, topical for actinic keratosis and superficial tumors
• Nicotinamide, vitamin B3 for skin cancer prevention
• Dexpanthenol, skin regenerating care after end of therapy

Frequently Asked Questions

Sources

• Gelbe Liste, Imiquimod active ingredient profile
• BfArM, German Federal Institute for Drugs and Medical Devices
• AWMF, Guidelines on actinic keratosis, basal cell carcinoma and genital warts
• German Dermatological Society